Network Pharmacology-Based Mechanism Exploration of Buyang Huanwu Decoction in Chronic Heart Failure

Wang Qili; Dong Jing

doi:10.23977/medsc.2026.070108

Network Pharmacology-Based Mechanism Exploration of Buyang Huanwu Decoction in Chronic Heart Failure

Download as PDF

DOI: 10.23977/medsc.2026.070108 | Downloads: 3 | Views: 91

Author(s)

Wang Qili ¹, Dong Jing ¹

Affiliation(s)

¹ Second Clinical Medical College of Shaanxi University of Traditional Chinese Medicine, Xianyang City, China

Corresponding Author

Dong Jing

ABSTRACT

Exploring the potential molecular mechanism of Buyang Huanwu Decoction in the treatment of chronic heart failure based on network pharmacology. Methods: The effective active ingredients of Buyang Huanwu Decoction were screened by searching TCMSP database, Chinese medicine Database@Taiwan and literature, and the targets of the effective active ingredients were predicted by SEA database and Binding Database. The targets related to chronic heart failure were obtained by Genecards, TTD, OMIM, Drugbank and PharmGkb Database, and the intersection targets of Buyang Huanwu Decoction and CHF were obtained. Cystoscape3.8.0 was used to construct a compound - disease - intersection target network diagram. The String database was used to construct PPI network, and R4.0.3 software was used to perform GO function enrichment analysis and KEGG signal pathway enrichment analysis for the intersection targets. Results: 1) A total of 104 chemical components and 841 targets were screened out in Buyang Huanwu Decoction. A total of 2908 targets were collected for chronic heart failure. There were 404 intersection targets of Buyang Huanwu Decoction and chronic heart failure. 2) Through PPI network, 28 core targets were screened out. 3) GO biological enrichment results showed 3964 GO entries; KEGG analysis co-enriched PI3K-Akt,MAPK, ect. 191 signaling pathways. Conclusion: Buyanghuanwu decoction can treat chronic heart failure through multi-component, multi-target and multi-channel mechanism.

KEYWORDS

Buyang Huanwu Decoction; Chronic heart failure; Network pharmacology

CITE THIS PAPER

Wang Qili, Dong Jing. Network Pharmacology-Based Mechanism Exploration of Buyang Huanwu Decoction in Chronic Heart Failure. MEDS Clinical Medicine (2026). Vol. 7, No.1, 64-75. DOI: http://dx.doi.org/10.23977/medsc.2026.070108.

REFERENCES

[1] Wang Hua, Liang Yanchun. Chinese Guidelines for Diagnosis and Treatment of Heart Failure 2018 [J]. Chinese Journal of Cardiovascular Diseases, 2018, 46(10):760-789.
[2] VIRANI SS, ALONSO A, BENJAMIN EJ et al. Heart disease and stroke statistics-2020 update: a report from the american heart association[J]. Circulation 2020, 141(9):e139-e596.
[3] Hu Shengshou, Gao Runlin, Liu Lisheng, et al. Summary of the China Cardiovascular Disease Report 2018 [J]. Chinese Journal of Circulation Medicine 2019: 209-220
[4] Chen Kejie, Wu Zonggui, Zhu Mingjun, et al. Expert Consensus on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Chronic Heart Failure [J]. Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases 2016, 16(05):340-347.
[5] Li Jiebai, Wang Zhen, Dong Xin, et al. Effects of Bu Yang Huan Wu Decoction on Cardiac Calcium Transporter SERCA2a and Phosphoprotein in Rats with Diastolic Heart Failure [J]. Global Traditional Chinese Medicine, 2018, 11(07):1009-1013.
[6] Wang Zhen, Li Jiebai, Dong Xin, et al. Effects of Bu Yang Huan Wu Tang on α-MHC, β-MHC, Drp1 mRNA, and Mitochondrial Ultrastructure in Rats with Diastolic Heart Failure [J]. Journal of Beijing University of Chinese Medicine 2018, 41(12):1002-1006.
[7] Wang Zhen, Li Jiebai, Dong Xin, et al. Effects of Bu Yang Huan Wu Tang on Mitochondrial Energy Metabolism and AMPK/PPARα Signaling Pathway in Rats with Diastolic Heart Failure [J]. Chinese Journal of Experimental Formulary 2019, 25(09):12-17.
[8] Huang Xianna, Huang Ling, Luo Hongbo. Intervention Effects of Bu Yang Huan Wu Decoction on Myocardial Remodeling in Heart Failure Rats via the TGF-β1/Smads Pathway [J]. Pharmacology and Clinical Application of Traditional Chinese Medicine. 2019;35(05):15-20.
[9] Liu Zhihua, Sun Xiaobo. Network Pharmacology: New Opportunities for Modernizing Traditional Chinese Medicine [J]. Acta Pharmaceutica Sinica 2012, 47(06):696-703.
[10] Jiao Mei, Zhong Hanyu, Chen Keyan, et al. Quercetin Improves Myocardial Fibrosis in Rats with Chronic Heart Failure via the TGF-β1/Smad3 Signaling Pathway [J]. Advances in Anatomical Sciences 2020, 26(04):391-395.
[11] Zhang Yumin, Zhang Zhenye, Qian Lingling, et al. Quercetin Protects Myocardial Cells in Diabetic Rats via the AKT/FOXO3 Signaling Pathway [J]. Journal of Jiangsu University (Medical Edition):1-6.
[12] Zhang Hui-chao, Xu Li, Rui Hao-miao, et al. Role of Paeoniflorin in Anti-Angiotensin II-Induced Cardiomyopathy via miR-21/Smad7 Pathway [J]. Journal of Southeast University (Medical Science) 2018, 37(02):191-197.
[13] Tan Na, Fan Gan, Shao Qingrui, et al. Protective Effects and Mechanism of Paeoniflorin Against Doxorubicin-Induced Myocardial Cell Apoptosis [J]. Pharmacology and Clinical Application of Traditional Chinese Medicine 2020, 36(03):101-105.
[14] Li Shuang, Liu Lu, Hu Baorong, et al. The Effect and Mechanism of Baicalin in Delaying Myocardial Aging in Rats [J]. Journal of Traditional Chinese Medicine 2017, 45(06):57-61.
[15] Xiao Yichuan. Study on the Mechanism of Baicalin Regulating AMPK/TGF-β/Smads Signaling Pathway to Inhibit Myocardial Fibrosis [J]. Master's Thesis. Guangzhou Medical University; 2018.
[16] Liu Xin, Lin Lin, Ni Yajuan, et al. Luteolin alleviates mitochondrial damage in cardiomyocytes of isoproterenol-induced heart failure rats [J]. Chinese Journal of Geriatric Multiorgan Diseases 2019, 18(09):693-698.
[17] Liu Xin, Lin Lin, Zhang Chao-ying, et al. Luteolin inhibits DNA damage in peripheral blood lymphocytes of isoproterenol-induced heart failure rats [J]. Journal of Xi'an Jiaotong University (Medical Science Edition) 2019, 40(02):323-327.
[18] BINCHENG R, YUFEI Z, SHANSHAN L et al. Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways[J]. Journal of cellular and molecular medicine 2020, 24(21).
[19] Li Zhenyan, Chen Min, Dai Rilei, et al. The Role of PI3K and Akt in Cardiovascular Diseases [J]. Basic Medicine and Clinical Practice. 2019, 39(08):1200-1204.
[20] Yin Z-f, Wei Y-l, Wang X et al. Buyang Huanwu Tang inhibits cellular epithelial-to-mesenchymal transition by inhibiting TGF-β1 activation of PI3K/Akt signaling pathway in pulmonary fibrosis model in vitro[J]. BMC Complementary Medicine and Therapies 2020, 20(5).
[21] Chen Bowei, Zhou Shengqiang, Yi Jian, et al. Effects of Bu Yang Huan Wu Tang on PI3K, Akt, and PTEN Expression in a Cav-1-/- Mouse Cerebral Ischemia Model by Cav-1-/-[J]. Journal of Chinese Medicine Information. 2020;27(04):35-40.
[22] Dong Yuan, Wang Zhisheng, Zhang Jin, et al. Effects of Bu Yang Huan Wu Tang on Cognitive Function and PI3/KAKT Signaling Pathway in Rats with Focal Ischemia [J]. World Journal of Traditional Chinese Medicine, 2020, 15(05):743-747.
[23] Zheng Lixian: Study on the Effects of Bu Yang Huan Wu Tang on the Platelet PI3K/Akt Pathway in Rats with Acute Cerebral Ischemia-Reperfusion Injury [J]. Master's Thesis. Southern Medical University; 2017.
[24] ALESSANDRA G, MURIEL L, MINGCHUAN L et al. PI3K and calcium signaling in cardiovascular disease[J]. Circulation research 2017, 121(3).
[25] ZHANG X, YANG K, ZHANG H et al. Effect of typhaneoside on ventricular remodeling and regulation of PI3K/Akt/mTOR pathway[J]. Herz 2020, 45(Suppl 1):113-122.
[26] ZHANG L,GUO Z,WANG Y et al: The protective effect of kaempferol on heart via the regulation of Nrf2, NF-kappabeta,and PI3K/Akt/GSK-3beta signaling pathways in isoproterenol-induced heart failure in diabetic rats[J]. Drug Dev Res 2019, 80(3):294-309.
[27] WEEKS KL,BERNARDO BC,OOI JYY et al: The IGF1-PI3K-Akt signaling pathway in mediating exercise-induced cardiac hypertrophy and protection[J]. Adv Exp Med Biol 2017, 1000:187-210.
[28] NOZHAT Z, HEDAYATI M: PI3K/AKT pathway and its mediators in thyroid carcinomas[J]. Molecular Diagnosis & Therapy 2016, 20(1).
[29] ZHENG J, LIANG J, DENG X et al: Mitogen activated protein kinase signaling pathways participate in the active principle region of Buyang Huanwu decoction-induced differentiation of bone marrow mesenchymal stem cells[J]. Neural Regen Res 2012, 7(18):1370-1377.
[30] CHEN G, WU L, DENG C-Q: The effects of BuYang HuanWu Decoction and its effective components on proliferation-related factors and ERK1/2 signal transduction pathway in cultured vascular smooth muscle cells[J]. Journal of Ethnopharmacology 2011, 135(1).
[31] YU P, GUAN L, ZHOU L et al: Upregulation of glutamate metabolism by BYHWD in cultured astrocytes following oxygen-glucose deprivation/reoxygenation in part depends on the activation of p38 MAPK[J]. Exp Ther Med 2017, 13(6):3089-3096.
[32] ROMERO-BECERRA R, SANTAMANS AM, FOLGUEIRA C et al: p38 MAPK pathway in the heart: new insights in health and disease[J]. Int J Mol Sci 2020, 21(19).
[33] KOJONAZAROV B, NOVOYATLEVA T, BOEHM M et al: p38 MAPK inhibition improves heart function in pressure-loaded right ventricular hypertrophy[J]. Am J Respir Cell Mol Biol 2017, 57(5):603-614.
[34] ZHANG Q,LU L,LIANG T et al: MAPK pathway regulated the cardiomyocyte apoptosis in mice with post-infarction heart failure[J]. Bratisl Lek Listy 2017, 118(6):339-346.
[35] Shi Xiu-Juan, Wei Yi-Hong, Tang Jing-Yi, et al. Research Progress on Hif-1α in Traditional Chinese Medicine Treatment of Heart Failure [J]. Journal of Chinese Medicine 2020, 38(01):118-121.
[36] WINDAK R,MULLER J,FELLEY A et al: The AP-1 transcription factor c-Jun prevents stress-imposed maladaptive remodeling of the heart[J]. PLoS One 2013, 8(9):e73294.
[37] GHOSH AK: P300 in cardiac development and accelerated cardiac aging[J]. Aging Dis 2020,11(4):916-926.

Subscription

E-Mail Alert

Downloads:	10609
Visits:	814727

Network Pharmacology-Based Mechanism Exploration of Buyang Huanwu Decoction in Chronic Heart Failure

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US